Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced independent partnerships with two new companies: iTeos Therapeutics and Kodiak Sciences. Under the terms of each agreement, Adimab will use its proprietary platform to discover and/or optimize antibodies against targets chosen by each company, who will have the right to develop and commercialize all therapeutics antibodies resulting from the collaboration.
“About three years ago we started partnering with early stage companies that were pursuing very innovative and novel disease biology,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “These partnerships have been quite successful. Our partners can immediately leverage our industry-leading discovery capabilities at a relative cost. This allows our partners to focus on the underlying biology for their programs and rapidly develop a pre-clinical pipeline.“
“Adimab is clearly an excellent strategic fit for iTeos. The quality of Adimab’s platform has consistently generated leads that are superior to the output from competing technologies,” noted Christophe Quéva, Chief Scientific Officer of iTeos. “Also, the ease and speed with which we were able to come to business terms and finalize an agreement was a pleasant surprise. It allowed us to quickly move to the far more important part of the collaboration – generating high quality therapeutic candidates for our patients.”
In addition, Adimab announced that Eli Lilly and Company, Kite Pharma and Jounce Therapeutics have all exercised independent commercial licenses to antibody programs generated under existing collaborations.
“We are pleased with the success of our collaboration with Adimab. The versatility and quality of the Adimab platform have been instrumental in supporting our CAR T cell therapies beyond KTE-C19,” said Tony Polverino, Ph.D., Vice President, Research of Kite Pharma. “We look forward to continuing our partnership with Adimab to advance important therapies for cancer patients.”
Over the past seven years, Adimab has established funded discovery collaborations with over 35 companies. Adimab’s funded discovery partners include leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi, Takeda and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition to funded discovery programs, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Merck, Novo Nordisk, Biogen, and GSK for internal use.
Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.
Guy Van Meter, 603-653-5775
VP of Business Development
Chris Erdman or Cammy Duong, 781-235-3060
Source : businesswire.com